MindMed raises CAD$19.5 million selling units at CAD$3.25.
MindMed raises CAD$19.5 million selling units at CAD$3.25.
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
ATAI announces closing its Series D financing round, raising $157 million.
The Company expects to have ibogaine manufactured and in use for research by Q4.
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
The completed equity investment strengthens ties between MINDCURE and ATMA
Mydecine exports dried psilocybin mushrooms from Jamaica to Canada.
Novamind reports rising revenues and cash on hand of CAD$10 million.
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now